Core Viewpoint - The stock of Kefu Medical (301087) has shown a positive performance with a closing price of 55.2 yuan, reflecting a 1.28% increase as of February 10, 2026, with significant trading activity and a notable net inflow of funds [1] Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, representing a year-on-year increase of 6.63% [2] - The net profit attributable to shareholders reached 260 million yuan, up 3.3% year-on-year, while the net profit after deducting non-recurring items was 222 million yuan, reflecting a 1.46% increase [2] - In Q3 2025 alone, the company achieved a quarterly revenue of 902 million yuan, marking a significant year-on-year growth of 30.72% [2] - The quarterly net profit attributable to shareholders was approximately 92.83 million yuan, which is a 38.68% increase year-on-year, and the net profit after deducting non-recurring items was about 85.80 million yuan, up 62.68% [2] - The company's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan, while maintaining a gross profit margin of 53.35% [2] Market Activity - On February 10, 2026, the stock experienced a trading volume of 25,100 hands and a total transaction amount of 139 million yuan [1] - The net inflow of main funds was 10.61 million yuan, accounting for 7.65% of the total transaction amount, while retail investors saw a net outflow of 8.20 million yuan, representing 5.91% of the total [1]
股票行情快报：可孚医疗（301087）2月10日主力资金净买入1061.10万元